In Brief This Week: Compugen; Sirius Genomics; Olink Genomics; PerkinElmer; GATC Biotech | GenomeWeb

NEW YORK (GenomeWeb News) – Compugen this week said that it has inked a deal to license to an unnamed diagnostic firm the biomarker candidate CGEN-226 for early detection of preeclampsia. Compugen used its in silico platform to identify the marker, which is a soluble splice variant of the vascular endothelial growth factor. (This brief has been corrected to state that Compugen licensed the biomarker to the unnamed partner rather than from the partner.)

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.